Rhumbline Advisers Igm Biosciences, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 22,726 shares of IGMS stock, worth $392,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,726

Previous 20,091 13.12%

Holding current value

$392,250

Previous $193,000 19.17%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$6.51 - $11.47 $17,153 - $30,223	2,635 Added 13.12%	22,726 $156,000
Q1 2024 May 09, 2024	BUY	$8.68 - $17.36 $7,699 - $15,398	887 Added 4.62%	20,091 $193,000
Q4 2023 Feb 08, 2024	BUY	$3.94 - $8.79 $2,001 - $4,465	508 Added 2.72%	19,204 $159,000
Q3 2023 Nov 09, 2023	SELL	$6.66 - $10.64 $14,345 - $22,918	-2,154 Reduced 10.33%	18,696 $156,000
Q2 2023 Aug 08, 2023	BUY	$8.86 - $14.0 $52,406 - $82,810	5,915 Added 39.6%	20,850 $192,000
Q1 2023 May 11, 2023	BUY	$13.74 - $25.76 $2,802 - $5,255	204 Added 1.38%	14,935 $205,000
Q4 2022 Feb 14, 2023	BUY	$15.45 - $26.02 $7,585 - $12,775	491 Added 3.45%	14,731 $251,000
Q3 2022 Nov 10, 2022	BUY	$15.42 - $27.01 $20,924 - $36,652	1,357 Added 10.53%	14,240 $324,000
Q2 2022 Aug 11, 2022	BUY	$13.27 - $25.5 $48,581 - $93,355	3,661 Added 39.7%	12,883 $232,000
Q1 2022 May 12, 2022	BUY	$13.42 - $29.73 $17,553 - $38,886	1,308 Added 16.53%	9,222 $247,000
Q4 2021 Feb 10, 2022	SELL	$27.59 - $66.39 $3,917 - $9,427	-142 Reduced 1.76%	7,914 $232,000
Q3 2021 Nov 12, 2021	BUY	$65.76 - $90.65 $23,739 - $32,724	361 Added 4.69%	8,056 $530,000
Q2 2021 Aug 05, 2021	BUY	$57.98 - $96.6 $2,319 - $3,864	40 Added 0.52%	7,695 $640,000
Q1 2021 May 06, 2021	SELL	$71.56 - $121.23 $22,612 - $38,308	-316 Reduced 3.96%	7,655 $587,000
Q4 2020 Feb 10, 2021	BUY	$47.41 - $115.03 $19,912 - $48,312	420 Added 5.56%	7,971 $704,000
Q3 2020 Nov 12, 2020	SELL	$43.0 - $84.01 $54,180 - $105,852	-1,260 Reduced 14.3%	7,551 $557,000
Q2 2020 Aug 13, 2020	BUY	$51.3 - $75.21 $199,095 - $291,890	3,881 Added 78.72%	8,811 $643,000
Q1 2020 May 06, 2020	BUY	$31.51 - $73.75 $155,344 - $363,587	4,930 New	4,930 $277,000

Others Institutions Holding IGMS

# of Institutions

Shares Held

21.4M

Call Options Held

39.5K

Put Options Held

16.5K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Igm Biosciences, Inc. Transaction History